Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03884556 · ClinicalTrials.gov registry record · Phase 1
TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers
A Phase 1 study, sponsored by Trishula Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
NCT03884556 is a Phase 1 study that has completed, run by Trishula Therapeutics. The registered enrollment target is 56 participants.
The verdict
NCT03884556, a Phase 1 study, has completed, sponsored by Trishula Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
Study Summary
This is a phase 1/1b study of TTX-030, an antibody that inhibits CD39 enzymatic activity, leading to accumulation of pro-inflammatory adenosine triphosphate (ATP) and reduction of immunosuppressive adenosine, which may change the tumor microenvironment and promote anti-tumor immune response. This trial will study the safety, tolerability, pharmacokinetics, and anti-tumor activity of TTX-030 as a single agent and in combination with an approved anti-PD-1 immunotherapy and standard chemotherapies.
Interventions
- DRUG Pembrolizumab
- DRUG Gemcitabine
- DRUG nab paclitaxel
- DRUG TTX-030
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2019-04-10 |
| Est. Completion | 2023-09-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03884556
The ClinicalTrials.gov registry entry for NCT03884556 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Trishula Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Pembrolizumab is the first listed.
NCT03884556 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03884556 about?
NCT03884556 is a clinical study titled "TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers". This is a phase 1/1b study of TTX-030, an antibody that inhibits CD39 enzymatic activity, leading to accumulation of pro-inflammatory adenosine triphosphate (ATP) and reduction of immunosuppressive adenosine, which may change the tumor microenvironment and promote anti-tumor immune response. This t...
What is the current status of trial NCT03884556?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2019-04-10. Estimated completion is 2023-09-29.
What interventions are being tested in trial NCT03884556?
The interventions under investigation include: Pembrolizumab (DRUG), Gemcitabine (DRUG), nab paclitaxel (DRUG), TTX-030 (DRUG).
Who is sponsoring clinical trial NCT03884556?
This trial is sponsored by Trishula Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.